Anti-angiogenic therapy in renal cell cancer.

Journal Article (Journal Article;Review)

Angiogenesis is an important hallmark of RCC, reflected in the natural history, Histology, genetics and now therapeutics of this disease. Clearly, the pro-angiogenic growth factor VEGF is a functional drug target in RCC and many strategies to inhibit this biology have shown clinical benefit. Multi-targeted TKI that inhibit VEGFRs have been approved by the FDA as standard treatment for advanced RCC. Pharmacodynamyc studies suggest that these agents and others also have anti-angiogenic effects. Currently, studies combining VEGFR-targeted strategies with other anti-angiogenic agents, including anti-VEGF antibodies, IFN or mTOR inhibitors, are underway. However, to what extent the clinical benefit of anti-angiogenic strategies in RCC can be built upon is unknown.

Full Text

Duke Authors

Cited Authors

  • Srinivasan, R; Armstrong, AJ; Dahut, W; George, DJ

Published Date

  • May 2007

Published In

Volume / Issue

  • 99 / 5 Pt B

Start / End Page

  • 1296 - 1300

PubMed ID

  • 17441927

International Standard Serial Number (ISSN)

  • 1464-4096

Digital Object Identifier (DOI)

  • 10.1111/j.1464-410X.2007.06834.x


  • eng

Conference Location

  • England